Naina Bashin, Ph.D., Chief Business Officer

Oct. 12 | 11:00am | BlueRock Therapeutics Ballroom

Boston, MA

In-person Presentation

Ensoma is expanding the reach of the curative power of precision genomic medicine by pioneering an off-the-shelf and portable in vivo approach using its Engenious™ vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning directly to hematopoietic stem cells or the various cell types that arise from these cells, such as T cells, B cells, and myeloid cells. As a result, Ensoma’s therapies can be delivered for both rare and common diseases as a single injection in a diverse range of settings, including outpatient and settings where access to sophisticated healthcare systems may be limited.


By using this website you agree to accept our Privacy Policy and Terms & Conditions